New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphomaNews-Medical.netAbout 20,000 people in the United States were diagnosed with iNHL in 2012 and approximately 7,000 died of the disease. The standard treatment for iNHL is a co…
MedscapeIdelalisib and rituximab extends survival in CLL patientsThe Oncology Report… rituximab extends survival in CLL patients. Adding idelalisib to rituximab significantly extends survival in patients with heavily pretreated relapsed chronic lymph…
Idelalisib Shows Efficacy in Relapsed CLL and LymphomaMedscapeThis trial showed that idelalisib used in combination with rituximab (Rituxan, Genentech/Roche) offered an option for patients with relapsed CLL who were unable to tolerate chemotherapy. The…
MedPage TodayRheuminations: 2013 Year in ReviewMedPage TodayHowever, by the end of 2013 we now have many comparator trials that show after failing an initial TNF inhibitor, there is equivalent or better efficacy when targeting different mechanisms with…
|
Pharmacyclics: Facts Behind $10B Market Cap
YCharts To date, first-line treatment has usually consisted of Roche’s (RHHBY) monoclonal antibody Rituxan (rituximab) – which is directed against the CD20 antigen found on B lymphocytes – combined with a multi-agent chemotherapy regimen, most often CHOP … |
Rheuminations: A Cautionary TaleMedPage TodayTwice weekly etanercept (Enbrel) was started, with no relief, and he subsequently was switched to adalimumab (Humira) and eventually to rituximab (Rituxan). Through the year of treatment with the biologics h…
|
$10B Market By 2022: Pharmacyclic’s Piece Of It
YCharts To date, first-line treatment has usually consisted of Roche’s monoclonal antibody Rituxan (rituximab) – which is directed against the CD20 antigen found on Beta lymphocytes – combined with a multi-agent chemotherapy regimen, most often CHOP … |
|
Preventing Cell Death from Infection: Scientists Demonstrate Powerful Method …
Lab Manager Laboratory News Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find—relatively quickly and cheaply—antibodies that have a desired effect on cells. The TSRI scientists used the … |
|
Forecasting Earnings Growth And Profitability In The Biopharmaceutical Industry
Seeking Alpha … had approval to market AVONEX® interferon beta-1a for multiple sclerosis, RITUXAN® rituximab for lymphoma and rheumatoid arthritis, TYSABRI® natalizumab for multiple sclerosis and Crohn’s disease, and FUMADERM® dimethylfumarate for psoriasis. |
Scientists capture Y-shaped images of antibodies under normal conditionsAsahi ShimbunKYOTO–Japanese researchers have succeeded in capturing the first clear images under conditions close to inside of the human body of the Y-shaped structure of antibodi…